Russell M. Bauer

Russell M. Bauer

Auto-generated profile, based on publicly available information

Russell M. Bauer

Department of Clinical and Health Psychology, University of Florida, Gainesville, FL, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2020 in The Clinical Neuropsychologist
Verified
Journal Article
Closed access
DMDavid E. Marra
David E. Marra
KHKristin M. Hamlet
Kristin M. Hamlet
RBRussell M. Bauer
Russell M. Bauer
DBDawn Bowers
Dawn Bowers
Objective: Due to the recent COVID-19 pandemic, the field of neuropsychology must rapidly evolve to incorporate assessments delivered via telehealth, or teleneuropsychology (TNP). Given the increasing demand to deliver services electronically due to public health concerns, it is important to review available TNP validity studies. This systematic review builds upon the work of Brearly and colleagues’ (2017) meta-analysis and provides an updated review of the literature, with special emphasis on test-level validity data. Method: Using similar methodology as Brearly and colleagues (2017) three internet databases (PubMed, EBSCOhost, PsycINFO) were searched for relevant articles published since 2016. Studies with older adults (aged 65+) who underwent face-to-face and TNP assessments in a counterbalanced cross-over design were included. After review, 10 articles were retained. Combined with nine articles from Brearly’s analysis, a total of 19 studies were included in the systematic review. Results: Retained studies included samples from 5 different countries, various ethnic/cultural backgrounds, and diverse diagnostic populations. Test-level analysis suggests there are cognitive screeners (MMSE, MoCA), language tests (BNT, Letter Fluency), attention/working memory tasks (Digit Span Total), and memory tests (HVLT-R) with strong support for TNP validity. Other measures are promising but lack sufficient support at this time. Few TNP studies have done in-home assessments and most studies rely on a PC or laptop. Conclusions: Overall, there appears to be good support for TNP assessments in older adults. Challenges to TNP in the current climate are discussed. Finally, a provisional outline of viable TNP procedures used in our clinic is provided.

9 January 2019 in Brain Injury
Verified
Journal Article
Closed access
ZHZac Houck
Zac Houck
BABreton Asken
Breton Asken
RBRussell Bauer
Russell Bauer
JCJames Clugston
James Clugston
Objective: To investigate potential predictors of acute post-concussion symptom severity in a university population. Methods: Data were obtained from the University of Florida Student Health Care Center Concussion Databank. Symptom severity, measured by the Sport Concussion Assessment Tool – third edition Symptom Evaluation (S3SE), was analyzed at 0–3 (n = 99) and 7–14 days (n = 56) post-concussion. Participants were 99 (56 females; age range: 18–30) students from the University of Florida who had been referred to the center’s Concussion Clinic. Independent samples t-test and Mann–Whitney U were used to assess group differences in overall and domain-specific symptom severity, respectively. Hierarchical regressions were used to assess predictors of symptom severity at 0–3 and 7–14 days, as well as residual symptom change between time points. Results: Female sex (β = .293; p = .002) and history of ADHD (β = .312; p = .001) predicted greater symptom severity at 0–3 days. History of motion sickness predicted lower symptom severity (β = −.199; p = .033). ADHD (β = .284; p = .009) and higher 0–3-day physical symptoms (β = .552; p < .001) predicted greater symptom severity at 7–14 days. ADHD predicted residual symptom severity change between time points (β = .433; p = .001). Conclusion: ADHD, female sex, and acute physical symptoms (0–3 days) represent risk factors for greater symptom severity in the first two weeks post-concussion among college students.

3 June 2019 in Journal of Clinical and Experimental Neuropsychology
Verified
Journal Article
Closed access
ASAdrian Svingos
Adrian Svingos
BABreton M. Asken
Breton M. Asken
MJMichael S. Jaffee
Michael S. Jaffee
RBRussell M. Bauer
Russell M. Bauer
SHShelley C. Heaton
Shelley C. Heaton
Prognostic modeling in moderate to severe traumatic brain injury (TBI) has historically focused primarily on the projection of crude outcomes such as the risk of mortality and disability. Initial work in this area has perpetuated the notion that prognosis after moderate to severe TBI can be measured as a single, static, and dichotomous outcome. However, more recent conceptualizations describe moderate to severe TBI as the initiation of a chronic disease state with high levels of inter-individual variability in terms of symptom manifestation and disease progression. Unfortunately, existing prognostic models provide limited insight into the extent of chronic cognitive and neurodegenerative changes experienced by moderate to severe TBI survivors. Though prior research has identified a variety of acute factors that appear to influence post-injury cognitive and neuropathological outcomes, an empirically supported framework for prognostic modeling of these injury-distal outcomes does not exist. The current review considers the literature on an expanded array of empirically supported predictors (both premorbid and injury-related) in association with long-term sequelae of moderate to severe TBI. We also provide a theoretical framework and statistical approach for prognostic modeling in moderate to severe TBI in order to unify efforts across research groups and facilitate important progress in this research area.

31 January 2019 in Brain Injury
Verified
Journal Article
Closed access
ASAdrian Svingos
Adrian Svingos
BABreton M. Asken
Breton M. Asken
RBRussell M. Bauer
Russell M. Bauer
SDSteven Trent DeKosky
Steven Trent DeKosky
GHGabrielle A. Hromas
Gabrielle A. Hromas
JCJames R. Clugston
James R. Clugston
Objective: Explore changes in micro-RNA (miRNA) expression in blood after sport-related concussion (SRC) in collegiate athletes. Methods: Twenty-seven collegiate athletes (~41% male, ~75% white, age 18.8 ± 0.8 years) provided both baseline and post-SRC blood samples. Serum was analyzed for expression of miR-153-3p (n = 27), miR-223-3p (n = 23), miR-26a-5p (n = 26), miR-423-3p (n = 23), and miR-let-7a-5p (n = 23) at both time points via quantitative polymerase chain reaction (qPCR). Nonparametric analyses were used to compare miRNA expression changes between baseline and SRC and to evaluate associations with clinical outcomes (symptom severity, cognition, balance, and oculomotor function, and clinical recovery time). Results: Participants manifested a significant increase in miRNA expression following SRC for miR153-3p (Z = −2.180, p = .029, 59% of the participants increased post-SRC), miR223-3p (Z = −1.998, p = .046, 70% increased), and miR-let-7a-5p (Z = −2.190, p = .029, 65% increased). There were no statistically significant associations between changes in miRNA expression and clinical test scores, acute symptom severity, or clinical recovery time. Conclusion: MiR-153-3p, miR-223-3p, and miR-let-7a-5p were significantly upregulated acutely following SRC in male and female collegiate athletes compared to baseline levels, though several athletes demonstrated no change or a decrease in expression. The biological mechanisms and functional implications of the increased expression of these circulating miRNA are unclear and require more research, as does their relevance to clinical outcomes.

19 September 2019 in The Clinical Neuropsychologist
Verified
Journal Article
Closed access
MCMichael D. Chafetz
Michael D. Chafetz
RBRussell M. Bauer
Russell M. Bauer
PHPaige S. Haley
Paige S. Haley
Objective: This paper aims to develop diagnostic criteria for factitious disorder (FD) and a heuristic for research by creating standards for delineating criterion groups. Method: Both FD and malingering are conceptualized within a rubric of illness-deception. The history of FD research was compared to the research history on malingering. Differences in the measurement of these constructs were described. The potential utility of performance validity tests (PVTs) and symptom validity tests (SVTs) in FD is discussed in light of successful applications in malingering. Methods for obtaining evidence for FD are delineated in a table of diagnostic criteria. Results: The comparison of FD and malingering research shows that the scientific measurement of malingering evolved rapidly with the introduction of forced-choice validity testing and cogent guidelines for the formation of criterion groups. Likewise, PVTs and SVTs hold promise as methods of measuring deceptive behavior in FD. The most salient differences between FD and malingering are understood to be matter of context/setting: malingering occurs in an external incentive context, while FD occurs in a medical/psychological context. Guidelines to assess FD are developed to fill the need for known-groups research. Conclusions: Evidence for FD, a form of illness-deception, can be obtained by using validity testing, which, together with careful clinical observation, allows for the development of probabilistic diagnostic criteria. Similar to the other form of illness-deception – malingering – these criteria can be used to form known groups for research.

1 June 2021 in Contemporary Clinical Trials Communications
Verified
Journal Article
Open access
NMNicole C.R. McLaughlin
Nicole C.R. McLaughlin
DDDarin D. Dougherty
Darin D. Dougherty
EEEmad Eskandar
Emad Eskandar
HWHerbert Ward
Herbert Ward
KFKelly D. Foote
Kelly D. Foote
BGBenjamin D. Greenberg
Benjamin D. Greenberg
Obsessive-compulsive disorder (OCD), a leading cause of disability, affects ~1–2% of the population, and can be distressing and disabling. About 1/3 of individuals demonstrate poor responsiveness to conventional treatments. A small proportion of these individuals may be deep brain stimulation (DBS) candidates. Candidacy is assessed through a multidisciplinary process including assessment of illness severity, chronicity, and functional impact. Optimization failure, despite multiple treatments, is critical during screening. Few patients nationwide are eligible for OCD DBS and thus a multi-center approach was necessary to obtain adequate sample size. The study was conducted over a six-year period and was a NIH-funded, eight-center sham-controlled trial of DBS targeting the ventral capsule/ventral striatum (VC/VS) region. There were 269 individuals who initially contacted the sites, in order to achieve 27 participants enrolled. Study enrollment required extensive review for eligibility, which was overseen by an independent advisory board. Disabling OCD had to be persistent for ≥5 years despite exhaustive medication and behavioral treatment. The final cohort was derived from a detailed consent process that included consent monitoring. Mean illness duration was 27.2 years. OCD symptom subtypes and psychiatric comorbidities varied, but all had severe disability with impaired quality of life and functioning. Participants were randomized to receive sham or active DBS for three months. Following this period, all participants received active DBS. Treatment assignment was masked to participants and raters and assessments were blinded. The final sample was consistent in demographic characteristics and clinical features when compared to other contemporary published prospective studies of OCD DBS. We report the clinical trial design, methods, and general demographics of this OCD DBS sample.